New drug NTR-1011 tested for autoimmune diseases
NCT ID NCT07237659
First seen Nov 20, 2025 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This early-stage trial tested the safety of a new drug called NTR-1011 in 36 healthy adults and people with lupus or rheumatoid arthritis. The study aimed to find a safe dose and see how the drug behaves in the body. It is a first step toward possibly developing a new treatment for these autoimmune conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE (SYSTEMIC LUPUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Clinical Trials Medical Group
Glendale, California, 91206, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NTR-1011
What this could lead to
If successful, this could point toward a new treatment option for lupus and rheumatoid arthritis by controlling the immune system's attack on the body.
What could go wrong
This is a very early Phase 1 trial with only 36 people, focused on safety. It is too soon to know if NTR-1011 will work for patients, and many early-stage drugs fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.